Repare Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.40 Mil. Repare Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.01 Mil. Repare Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $212.08 Mil.
Repare Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.02.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Repare Therapeutics's Debt-to-Equity or its related term are showing as below:
RPTX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.02 Med: 0.02 Max: 0.03
Current: 0.02
During the past 7 years, the highest Debt-to-Equity Ratio of Repare Therapeutics was 0.03. The lowest was -0.02. And the median was 0.02.
Repare Therapeutics Debt-to-Equity Historical Data
The historical data trend for Repare Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Repare Therapeutics Annual Data
|
|
Trend |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
-0.02 |
0.01 |
0.03 |
0.02 |
0.02 |
|
Repare Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.02 |
0.02 |
0.02 |
0.02 |
0.02 |
Competitive Comparison
For the Biotechnology subindustry, Repare Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repare Therapeutics Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Repare Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Repare Therapeutics's Debt-to-Equity falls into.
Repare Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Repare Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Repare Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repare Therapeutics (Repare Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
7210 Frederick-Banting Street, Suite 100, Saint-Laurent, QC, CAN, H4S 2A1
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
Executives
| Biotechnology Value Fund L P |
other: See Explanation of Responses |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Michael Zinda |
officer: EVP, Chief Science Officer |
C/O REPARE THERAPEUTICS INC., 7210 FREDERICK-BANTING, SUITE 100, ST-LAURENT A8 H4S 2A1 |
| Susan Molineaux |
director |
C/O CALITHERA BIOSCIENCES, INC., 343 OYSTER POINT BLVD., SUITE 200, SOUTH SAN FRANCISCO CA 94080 |
| Davis Jerel |
director, 10 percent owner |
ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
| Versant Ventures V, Llc |
10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Versant Vantage I, L.p. |
10 percent owner |
ONE SANSOME, SUITE 1650, SAN FRANCISCO CA 94104 |
| Thomas Civik |
director |
C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141 |
| Mark N Lampert |
10 percent owner |
1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104 |
| Biotechnology Value Fund Ii Lp |
other: See Explanation of Responses |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Bvf Inc/il |
10 percent owner |
44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
| Biotechnology Value Trading Fund Os Lp |
other: See Explanation of Responses |
P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
| Bvf Partners Os Ltd. |
other: See Explanation of Responses |
P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
| Bvf Partners L P/il |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Gp Holdings Llc |
10 percent owner |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
| Bvf Ii Gp Llc |
other: See Explanation of Responses |
44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104 |
Repare Therapeutics (Repare Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RPTX has been successfully added to your